Follow on Google News News By Tag * Pharmacogenomics Assays * Women's Health Tests * Infectious Diseases * Genetic Disorders Tests * AutoGenomics MPA technology * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | AutoGenomics granted United States patent for Multi-Patient Array (MPA) technologyAutoGenomics’ “This differentiating technology creates increased efficiencies for AutoGenomics’ Assays utilizing AutoGenomics’ AutoGenomics currently offers more than 25 assays which incorporate the MPA including: 1. INFINITI® CYP450 2D6-Duplex Assay – Identifies 16 mutations in Cytochrome P450 2D6 gene (including deletions and duplications) 2. INFINITI® Factors Plus QUAD – Identifies 5 mutations in Factor II, Factor V-Leiden and MTHFR genes in 4 discrete samples simultaneously. 3. INFINITI® HPV-HR HEX Assay - Identifies 14 High Risk Genotypes of Human Papillomavirus Virus (HPV) in 6 discrete samples simultaneously. 4. INFINITI® MTBC-O Assay – Identifies Mycobacterium tuberculosis complex in 8 discrete samples simultaneously. The above mentioned tests are for research use only. About AutoGenomics AutoGenomics, Inc., a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and cancer. With the discovery of genes and their link to various disease states, the AutoGenomics’ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|